Shattuck Labs, Inc.
STTKHealthcare|Biotechnology|US
$4.62
+0.13 (+2.90%)
DCF Value
$0.61
Tangible Book / Share
$1.06
Cash / Share
$1.07
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07753850 A Study of SL-325 in Crohn's Disease Patients | Crohn's Disease | P2 | Recruiting | 232 | RCT, Double-blind | SL-325, Placebo |
| NCT07158437 Phase 1 Study of SL-325 in Healthy Volunteers | Healthy Volunteers | P1 | Active | 72 | RCT, Double-blind | SL-325 |
| NCT04502888 Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin | Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck | P1 | Terminated | 5 | Open-label | Drug: SL-172154 |
| NCT05483933 Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer | P1 | Completed | 86 | Open-label | Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154 |
| NCT04406623 Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer | Ovarian Cancer, Fallopian Tube Cancer | P1 | Completed | 27 | Open-label | SL-172154 |
| NCT05275439 Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | Acute Myeloid Leukemia, Myelodysplastic Syndromes | P1 | Terminated | 106 | Open-label | SL-172154, Azacitidine (AZA), Venetoclax |
| NCT03894618 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Squamous Cell Carcinoma of the Head and Neck, Melanoma | P1 | Completed | 49 | Open-label | SL-279252 |